Abstract
Primary Budd-Chiari syndrome (BCS) is defined as hepatic venous outflow obstruction from small hepatic veins to the inferior vena cava (IVC), due to thrombosis or fibrous stenosis of these veins. In Western countries, one or multiple prothombotic diseases are usually identified, mainly myeloproliferative neoplasms. New noninvasive diagnostic tools facilitate the diagnosis of these causes which may be difficult to detect in the presence of portal hypertension (PH) or liver failure.
The spectrum of symptoms ranges from an absence of signs to fulminant hepatic failure. Specific and sensitive criteria for the diagnosis of BCS have been described with Doppler ultrasound or contrast imaging (CT or MRI) so that liver biopsy is not necessary in most situations.
A minimally invasive therapeutic strategy is currently proposed for BCS patients in the West. The first step includes anticoagulant therapy and treatment of the identified cause when appropriate, to avoid the recurrence or extension of thrombosis, and nonspecific management of the complications of PH. The second step includes an attempt to recanalize and reestablish physiological venous outflow, with angioplasty/stenting. When symptoms are not resolved by this approach, the disease is managed by TIPS. If TIPS fail, or in patients with HCC, liver transplantation is performed. Long-term management must focus on close follow-up of the cause and nodules to prevent recurrent thrombosis, the complications of treatment and a misdiagnosis of HCC.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- APLS:
-
Antiphospholipid syndrome
- BCS:
-
BUDD Chiari Syndrome
- BMB:
-
Bone marrow biopsy
- BMI:
-
Body mass index
- HCC:
-
Hepatocellular carcinoma
- HV:
-
Hepatic vein
- IVC:
-
Inferior vena cava
- MPN:
-
Myeloproliferative neoplasm
- OLT:
-
Orthotopic liver transplantation
- OP:
-
Oestro-progestative
- PH:
-
Portal hypertension
- PMI:
-
Per million inhabitants
- PNH:
-
Paroxysomal noctural haemoglobinuria
- TIPS:
-
Transjugular porto systemic shunt
References
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64(1):179–202.
DeLeve LD, Valla D-C, Garcia-Tsao G, American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology. 2009;49(5):1729–64.
Allaire M, Ollivier-Hourmand I, Morello R, Chagneau-Derrode C, Dumortier J, Goria O, et al. P1288: Budd chiari syndrome (BCS) in France from a large national cohort. J Hepatol. 2015;62:S842.
Ki M, Choi HY, Kim K-A, Kim BH, Jang ES, Jeong S-H. Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study. Liver Int. 2016;36(7):1067–73.
Zhang W, Qi X, Zhang X, Su H, Zhong H, Shi J, et al. Budd-Chiari syndrome in China: a systematic analysis of epidemiological features based on the Chinese literature survey. Gastroenterol Res Pract. 2015;2015:738548.
Smalberg JH, Arends LR, Valla DC, Kiladjian J-J, Janssen HLA, Leebeek FWG. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120(25):4921–8.
Kiladjian J-J, Cervantes F, Leebeek FWG, Marzac C, Cassinat B, Chevret S, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111(10):4922–9.
Poisson J, Plessier A, Kiladjian J-J, Turon F, Cassinat B, Andreoli A, et al. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study. J Hepatol. Epub 2017 May 5
Hayek G, Ronot M, Plessier A, Sibert A, Abdel-Rehim M, Zappa M, et al. Long-term outcome and analysis of dysfunction of transjugular intrahepatic portosystemic shunt placement in chronic primary Budd-Chiari syndrome. Radiology. 2017;283(1):280–92. Epub 2016 Oct 31
De Stefano V, Qi X, Betti S, Rossi E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost. 2016;115(2):240–9.
Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M, et al. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Am J Hematol. 2017;92(2):187–95.
Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96(7):2364–8.
Zhang P, Ma H, Min Q, Zu M, Lu Z. CALR mutations in Chinese Budd-Chiari syndrome patients. Eur J Gastroenterol Hepatol. 2016;28(3):361–2.
Austin SK, Lambert JR. The JAK2 V617F mutation and thrombosis. Br J Haematol. 2008;143(3):307–20.
Teofili L, Martini M, Iachininoto MG, Capodimonti S, Nuzzolo ER, Torti L, et al. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood. 2011;117(9):2700–7.
Helman R, Pereira W de O, Marti LC, Campregher PV, Puga RD, Hamerschlak N, et al. Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari syndrome without myeloproliferative neoplasm. Br J Haematol. Epub 2016 Sep 21.
Seijo S, Plessier A, Hoekstra J, Dell’era A, Mandair D, Rifai K, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology. 2013;57(5):1962–8.
Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151(3):167–75.
De Stefano V, Za T, Ciminello A, Betti S, Rossi E. Causes of adult splanchnic vein thrombosis in the mediterranean area. Mediterr J Hematol Infect Dis. 2011;3(1):e2011063.
Jadallah KA, Sarsak EW, Khazaleh YM, Barakat RMK. Budd-Chiari syndrome associated with coeliac disease: case report and literature review. Gastroenterol Rep. Epub 2016 Sep 7.
Ben Ghorbel I, Ennaifer R, Lamloum M, Khanfir M, Miled M, Houman MH. Budd-Chiari syndrome associated with Behçet’s disease. Gastroenterol Clin Biol. 2008;32(3):316–20.
Seyahi E, Caglar E, Ugurlu S, Kantarci F, Hamuryudan V, Sonsuz A, et al. An outcome survey of 43 patients with Budd-Chiari syndrome due to Behçet’s syndrome followed up at a single, dedicated center. Semin Arthritis Rheum. 2015;44(5):602–9.
Bissonnette J, Durand F, de Raucourt E, Ceccaldi P-F, Plessier A, Valla D, et al. Pregnancy and vascular liver disease. J Clin Exp Hepatol. 2015;5(1):41–50.
Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benhamou JP. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology. 1986;90(4):807–11.
Faraoun SA, Boudjella MEA, Debzi N, Benidir N, Afredj N, Guerrache Y, et al. Budd-Chiari syndrome: an update on imaging features. Clin Imaging. 2016;40(4):637–46.
Pariente D, Franchi-Abella S. Paediatric chronic liver diseases: how to investigate and follow up? Role of imaging in the diagnosis of fibrosis. Pediatr Radiol. 2010;40(6):906–19.
Cazals-Hatem D, Vilgrain V, Genin P, Denninger M-H, Durand F, Belghiti J, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology. 2003;37(3):510–9.
Moucari R, Rautou P-E, Cazals-Hatem D, Geara A, Bureau C, Consigny Y, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut. 2008;57(6):828–35.
Raza SA, Jang H-J, Kim TK. Differentiating malignant from benign thrombosis in hepatocellular carcinoma: contrast-enhanced ultrasound. Abdom Imaging. 2014;39(1):153–61.
Mukund A, Pargewar SS, Desai SN, Rajesh S, Sarin SK. Changes in liver congestion in patients with Budd-Chiari syndrome following endovascular interventions: assessment with transient elastography. J Vasc Interv Radiol. Epub 2017 Jan 30.
Faraoun SA, Boudjella MEA, Debzi N, Afredj N, Guerrache Y, Benidir N, et al. Budd-Chiari syndrome: a prospective analysis of hepatic vein obstruction on ultrasonography, multidetector-row computed tomography and MR imaging. Abdom Imaging. 2015;40(6):1500–9.
Martens P, Maleux GA, Devos T, Monbaliu D, Heye S, Verslype C, et al. Budd-Chiari syndrome: reassessment of a step-wise treatment strategy. Acta Gastro-Enterol Belg. 2015;78(3):299–305.
Sempoux C, Paradis V, Komuta M, Wee A, Calderaro J, Balabaud C, et al. Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders. J Hepatol. 2015;63(5):1173–80.
Garcia-Pagán JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135(3):808–15.
Plessier A, Sibert A, Consigny Y, Hakime A, Zappa M, Denninger M-H, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology. 2006;44(5):1308–16.
Langlet P, Escolano S, Valla D, Coste-Zeitoun D, Denie C, Mallet A, et al. Clinicopathological forms and prognostic index in Budd-Chiari syndrome. J Hepatol. 2003;39(4):496–501.
Rautou P-E, Moucari R, Cazals-Hatem D, Escolano S, Denié C, Douarin L, et al. Levels and initial course of serum alanine aminotransferase can predict outcome of patients with Budd-Chiari syndrome. Clin Gastroenterol Hepatol. 2009;7(11):1230–5.
Rautou P-E, Moucari R, Escolano S, Cazals-Hatem D, Denié C, Chagneau-Derrode C, et al. Prognostic indices for Budd-Chiari syndrome: valid for clinical studies but insufficient for individual management. Am J Gastroenterol. 2009;104(5):1140–6.
Darwish Murad S, Kim WR, de Groen PC, Kamath PS, Malinchoc M, Valla D-C, et al. Can the model for end-stage liver disease be used to predict the prognosis in patients with Budd-Chiari syndrome? Liver Transpl. 2007;13(6):867–74.
Min AD, Atillasoy EO, Schwartz ME, Thiim M, Miller CM, Bodenheimer HC. Reassessing the role of medical therapy in the management of hepatic vein thrombosis. Liver Transpl Surg. 1997;3(4):423–9.
Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology. 1999;30(1):84–9.
Ouwendijk RJ, Koster JC, Wilson JH, Stibbe J, Lameris JS, Visser W, et al. Budd-Chiari syndrome in a young patient with anticardiolipin antibodies: need for prolonged anticoagulant treatment. Gut. 1994;35(7):1004–6.
Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51(1):210–8.
Plessier A, Rautou P-E, Valla D-C. Management of hepatic vascular diseases. J Hepatol. 2012;56(Suppl 1):S25–38.
Zaman S, Wiebe S, Bernal W, Wendon J, Czuprynska J, Auzinger G. Increased prevalence of heparin-induced thrombocytopenia in patients with Budd-Chiari syndrome: a retrospective analysis. Eur J Gastroenterol Hepatol. 2016;28(8):967–71.
Rautou P-E, Douarin L, Denninger M-H, Escolano S, Lebrec D, Moreau R, et al. Bleeding in patients with Budd-Chiari syndrome. J Hepatol. 2011;54(1):56–63.
Chagneau-Derrode C, Roy L, Guilhot J, Gloria O, Ollivier-Hourmand I, Bureau C, et al. Impact of cytoreductive therapy on the outcome of patients with myeloproliferative neoplasms and hepatosplanchnic vein thrombosis. 58th ed; 2013. p. 857A.
Desbois AC, Rautou PE, Biard L, Belmatoug N, Wechsler B, Resche-Rigon M, et al. Behcet’s disease in Budd-Chiari syndrome. Orphanet J Rare Dis. 2014;9:104.
Tripathi D, Sunderraj L, Vemala V, Mehrzad H, Zia Z, Mangat K, et al. Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome. Liver Int. 2017;37(1):111–20.
Zhang QQ, Xu H, Zu MH, Gu YM, Shen B, Wei N, et al. Strategy and long-term outcomes of endovascular treatment for Budd-Chiari syndrome complicated by inferior vena caval thrombosis. Eur J Vasc Endovasc Surg. 2014;47(5):550–7.
Huang Q, Shen B, Zhang Q, Xu H, Zu M, Gu Y, et al. Comparison of long-term outcomes of endovascular management for membranous and segmental inferior vena cava obstruction in patients with primary Budd-Chiari syndrome. Circ Cardiovasc Interv. 2016;9(3):e003104.
Qi X, Guo X, Fan D. Difference in Budd-Chiari syndrome between the West and China. Hepatology. 2015;62(2):656.
Fu Y-F, Li Y, Cui Y-F, Wei N, Li D-C, Xu H. Percutaneous recanalization for combined-type Budd-Chiari syndrome: strategy and long-term outcome. Abdom Imaging. 2015;40(8):3240–7.
Ding P-X, Zhang S-J, Li Z, Fu M-T, Hua Z-H, Zhang W-G. Long-term safety and outcome of percutaneous transhepatic venous balloon angioplasty for Budd-Chiari syndrome. J Gastroenterol Hepatol. 2016;31(1):222–8.
Fan X, Liu K, Che Y, Wang S, Wu X, Cao J, et al. Good clinical outcomes in Budd-Chiari syndrome with hepatic vein occlusion. Dig Dis Sci. 2016;61(10):3054–60.
Sharma VK, Ranade PR, Marar S, Nabi F, Nagral A. Long-term clinical outcome of Budd-Chiari syndrome in children after radiological intervention. Eur J Gastroenterol Hepatol. 2016;28(5):567–75.
Shalimar, Kumar A, Kedia S, Sharma H, Gamanagatti SR, Gulati GS, et al. Hepatic venous outflow tract obstruction: treatment outcomes and development of a new prognostic score. Aliment Pharmacol Ther. 2016;43(11):1154–67.
Tripathi D, Macnicholas R, Kothari C, Sunderraj L, Al-Hilou H, Rangarajan B, et al. Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. Aliment Pharmacol Ther. 2014;39(8):864–72.
Mentha G, Giostra E, Majno PE, Bechstein WO, Neuhaus P, O’Grady J, et al. Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol. 2006;44(3):520–8.
Potthoff A, Attia D, Pischke S, Mederacke I, Beutel G, Rifai K, et al. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. Liver Int. 2015;35(8):2042–9.
Westbrook RH, Lea NC, Mohamedali AM, Smith AE, Orr DW, Roberts LN, et al. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl. 2012;18(7):819–27.
Okuda H, Yamagata H, Obata H, Iwata H, Sasaki R, Imai F, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol. 1995;22(1):1–9.
Almdal TP, Sørensen TI. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver. Hepatology. 1991;13(4):650–5.
Rajani R, Melin T, Björnsson E, Broomé U, Sangfelt P, Danielsson A, et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival – an 18-year experience. Liver Int. 2009;29(2):253–9.
Ageno W, Dentali F, Pomero F, Fenoglio L, Squizzato A, Pagani G, et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari syndrome. Thromb Haemost. Epub 2017 Feb 9.
Cheng D, Xu H, Lu Z-J, Hua R, Qiu H, Du H, et al. Clinical features and etiology of Budd-Chiari syndrome in Chinese patients: a single-center study. J Gastroenterol Hepatol. 2013;28(6):1061–7.
Han G, Qi X, Zhang W, He C, Yin Z, Wang J, et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Radiology. 2013;266(2):657–67.
Qi X, Wu F, Fan D, Han G. Prevalence of thrombotic risk factors in Chinese Budd-Chiari syndrome patients: results of a prospective validation study. Eur J Gastroenterol Hepatol. 2014;26(5):576–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Plessier, A., Payancé, A., Valla, D. (2018). Budd-Chiari Syndrome: The Western Perspective. In: Berzigotti, A., Bosch, J. (eds) Diagnostic Methods for Cirrhosis and Portal Hypertension. Springer, Cham. https://doi.org/10.1007/978-3-319-72628-1_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-72628-1_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-72627-4
Online ISBN: 978-3-319-72628-1
eBook Packages: MedicineMedicine (R0)